报告名称：Sun Pharma (SUNP IN)Buy：Key readings from Taro’s 20F
报告类型：海外市场
报告日期：2015-07-02
研究机构：汇丰银行
页数：12
简介：Taro sees more price led growth in US in FY15: Taro reported FY15 total sales ofUSD863m, of which the US contributed cUSD777m (90.1% of total). US sales increasedby USD107.7m or 16.1% yoy in FY15, of which USD97.2m came from price increases in12 generic products (some of these include amiodarone, carbamezapine, clobetasol,phenytoin etc.). These products contributed 32% of sales in FY15 against 24% in FY14.
The overall impact of price led growth in sales is higher in FY15 (c90%) than in FY13(c84%). This is despite a fall in the largest selling product Nystatin/Triamcinolone, whichcontributed

下载地址：Sun Pharma (SUNP IN)Buy：Key readings from Taro’s 20F